Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc. reported operating expenses of $36.4 million, an increase of $2.0 million year-over-year, while revenue in the third quarter surpassed consensus expectations, prompting management to raise its guidance. The company is expected to sustain double-digit growth, fueled by increased utilization from a growing installed base of light adjustable lens technology (LDD), along with strategic initiatives aimed at enhancing lens volume engagement. Furthermore, management has upgraded gross margin guidance to a range of 76-77% for 2025, signaling potential for improved profitability alongside its commitment to managing operating expenses.

Bears say

RxSight Inc. has experienced declining utilization of its light adjustable lenses (LALs), with monthly utilization dropping to 8.0 LALs per light delivery device (LDD) in 3Q25, reflecting a downward trend both quarter-over-quarter and year-over-year. Revenue declined to $30.3 million, marking a 14% decrease year-over-year, and LDD placements fell significantly by 68% year-over-year and 38% quarter-over-quarter, suggesting disappointing commercial execution and limited market adoption. Additionally, increased competition in the intraocular lens market, along with the potential for a dilutive financing round, further exacerbates the risks associated with the company's future performance.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.